CD274 and primary cutaneous T-cell non-Hodgkin lymphoma: In a Phase1/2 trial of anti-PD-L1 (durvalumab) and lenalidomide in CTCL patients, Querfeld et al. showed that durvalumab and lenalidomide are associated with significant clinical activity in refractory and advanced patients [157].